Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06156410 · ClinicalTrials.gov registry record · Phase 1
Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas
A Phase 1 study of Osteosarcoma and Ewing Sarcoma, sponsored by Children's Hospital of Philadelphia.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 4
- Study locations
NCT06156410: Recruiting Phase 1 study of Osteosarcoma and Ewing Sarcoma, sponsored by Children's Hospital of Philadelphia.
NCT06156410 is a Phase 1 study of Osteosarcoma and Ewing Sarcoma that is actively recruiting participants, run by Children's Hospital of Philadelphia. The registered enrollment target is 30 participants, below the 301-participant average among 46 other Osteosarcoma trials with a reported enrollment target (90% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06156410, a Phase 1 study of Osteosarcoma and Ewing Sarcoma, is actively recruiting participants, sponsored by Children's Hospital of Philadelphia.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to better understand how safe and effective the drug cabozantinib in combination with high-dose ifosfamide is in the treatment of children and adults with relapsed/refractory sarcomas.
Primary Outcome
Toxicity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 (v5.0).
Conditions Studied
Interventions
- DRUG Cabozantinib
Study Locations (4)
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
- University of Pennsylvania - Philadelphia
California
- University of California San Francisco - San Francisco
Colorado
- Children's Hospital Colorado - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-10-24 |
| Est. Completion | 2028-11 |
| Phase | Phase 1 |
What NCT06156410 shows while recruiting
NCT06156410 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 301-participant average among 46 other Osteosarcoma trials with a reported enrollment target (90% lower).
The record links to 3 conditions, with Osteosarcoma appearing as the primary indexed condition, and to 1 intervention - of which Cabozantinib is the first listed.
NCT06156410 reports a single indexed study location in Pennsylvania, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT06156410 about?
NCT06156410 is a clinical study titled "Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas". The purpose of this study is to better understand how safe and effective the drug cabozantinib in combination with high-dose ifosfamide is in the treatment of children and adults with relapsed/refractory sarcomas.
What is the current status of trial NCT06156410?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2023-10-24. Estimated completion is 2028-11.
What conditions does trial NCT06156410 study?
This clinical trial studies the following conditions: Osteosarcoma, Ewing Sarcoma, Sarcomas.
What interventions are being tested in trial NCT06156410?
The interventions under investigation include: Cabozantinib (DRUG).
Who is sponsoring clinical trial NCT06156410?
This trial is sponsored by Children's Hospital of Philadelphia, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06156410 being conducted?
This trial has 4 study locations across California, Colorado, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteosarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06156410's enrollment target sits among peer trials
30 30th of 46 higher than 16 of 46 other Osteosarcoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Osteosarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
RECRUITING · Phase 1
-
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
RECRUITING · Phase 1
-
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
RECRUITING · Phase 1
-
Losartan + Sunitinib in Treatment of Osteosarcoma
RECRUITING · Phase 1
-
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI